Ph.D., University of Hamburg, Germany, Immunology, 2003.
M.S., University of Braunschweig, Germany, Study of Biotechnology, 1996.
My research addresses the influence of HIV sequence diversity on its recognition by cytotoxic T lymphocytes, as well as the factors governing the recognition of sequence variants both in HIV-infected subjects and in vaccine trial participants. More recently, my research also includes the assessment of immune responses to viral vectors used as immunogens in HIV vaccine trials to help understand how pre-existing cellular immunity to the vector influences the quality of vaccine-induced immune responses. In my role as the Associate Laboratory Director for the HVTN, I provide leadership and scientific support for the HVTN Laboratories. This includes (but is not restricted to) oversight of the Endpoints Laboratory, which is responsible for the generation of validated immunogenicity data for all HVTN trials, and of the R&D Laboratory, which provides ancillary and exploratory data leading to a more complete view of the immune responses generated by HIV vaccines.
(Reading, Writing, Speaking)
German: (Fluent, Fluent, Fluent)
Portuguese (Brazilian): (Fluent, Fluent, Fluent)
2006-2008, Instructor, Harvard University, Medical School
2006-2008, Assistant in Immunology, Massachusetts General Hospital, Partners AIDS Research Center, Infectious Diseases
2001-2006, Post-doctoral fellow, Harvard University, Medical School
2001-2006, Post-doctoral fellow, Massachusetts General Hospital, Partners AIDS Research Center, Infectious Diseases
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine.. 2013.
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001).. The Journal of infectious diseases. 207(2):248-56.. 2013.
Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus.. Journal of acquired immune deficiency syndromes (1999).. 2013.
Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials.. Journal of immunological methods. 394(1-2):84-93.. 2013.
Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection.. The Journal of infectious diseases.. 2013.
Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity.. Journal of virology. 86(12):6913-23.. 2012.
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67.. 2012.
A Robust Bayesian Random Effects Model for Nonlinear Calibration Problems.. Biometrics. 68(4):1103-12.. 2012.
Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.. Journal of immunological methods. 382(1-2):117-28.. 2012.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86.. 2012.
Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial. Retrovirology. 9(Suppl 2):P118.. 2012.
Preferential targeting of co-evolving Gag residues in long-term non progressors. Retrovirology. 9(Suppl 2):P278.. 2012.
High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control.. Journal of virology. 85(18):9334-45.. 2011.
Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.. The Journal of infectious diseases. 203(6):773-9.. 2011.
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.. Nature medicine. 17(3):366-71.. 2011.
Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies.. AIDS (London, England). 24(6):803-9.. 2010.
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice.. Journal of virology. 83(14):7305-21.. 2009.